Zomig 2.5mg. 5mg Tablets
PDF Leaflet Revision Date: 29 June 2015
Clinical Summary
Quick overview from the medicine insert
Indication
Acute treatment of migraine with or without aura in adults.
Dosage (summary)
Initial dose: 2.5 mg; may increase to 5 mg if needed. Max: 10 mg in 24 hours.
Onset of Action / Duration
Onset: 1 hour, Duration: 4-6 hours
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly patients
Pregnancy & Breastfeeding
Safety not established; not recommended during breastfeeding.
Key Drug Interactions
- Avoid other 5HT 1B/1D agonists within 12 hours
- Caution with SSRIs/SNRIs due to serotonin syndrome risk
Contraindications
- Hypersensitivity to components
- Severe hypertension
- Ischaemic heart disease
- Moderate to severe hepatic impairment
Common side effects
- Dizziness
- Nausea
- Somnolence
- Dry mouth
- Palpitations
Counselling Points
- Take as early as possible during a migraine attack
- Do not exceed recommended dose
- Inform about phenylalanine in Rapimelt
Serious warnings
- Risk of coronary vasospasm
- Evaluate cardiovascular status before use
- Potential for serotonin syndrome
Important Disclaimer
The Zomig 2.5mg. 5mg Tablets professional information leaflet below is the property of Astrazeneca Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
